pleconaril Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Pleconaril (Picovir) is an antiviral drug that was being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in patients exposed to picornavirus respiratory infections. Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus. It has shown useful activity against the dangerous enterovirus D68.   Wikipedia

Chemistry

  • SMILES: Cc1cc(CCCOc2c(C)cc(cc2C)c3noc(n3)C(F)(F)F)on1
  • InChIKey: KQOXLKOJHVFTRN-UHFFFAOYSA-N
  • Mol. Mass: 381.35
  • ALogP: 4.68
  • ChEMBL Molecule:
    pleconaril  
More Chemistry

Pharmacology

Alternative names

3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole | 3-(3,5-dimethyl-4((3-(3-methyl-5-isoxazolyl)propyl)phenyl)-5-trifluoromethyl)-1,2,4-oxadiazole | picovir | pleconaril | vp-63843 | win 63843 | win-63843

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Asthma (Phase 2)

Common Cold (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Enterovirus (Phase 2)

Picornaviridae Infections (Phase 2)

Rhinovirus (Phase 2)

Sepsis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue